Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 13/20 | 0.49 |
| ▸ | FNTB | P49356 | 13/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 12/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900048 | 0.87 | FNTA (0.58) | FNTAFNTBPGGT1B | |
| SCHEMBL4901285 | 0.85 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| SCHEMBL4901913 | 0.80 | FNTA (0.49) | FNTAFNTBPGGT1BKMT2AL3MBTL1 | |
| SCHEMBL4897001 | 0.73 | FNTA (0.48) | FNTAFNTBPGGT1BCHRM2 | |
| SCHEMBL4897156 | 0.73 | FNTA (0.64) | FNTAFNTBPGGT1B | |
| SCHEMBL4899984 | 0.71 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| SCHEMBL4894032 | 0.71 | FNTA (0.58) | FNTAFNTBPGGT1B | |
| SCHEMBL4899929 | 0.71 | FNTA (0.60) | FNTAFNTBPGGT1B | |
| SCHEMBL4893638 | 0.71 | FNTA (0.56) | FNTAFNTBPGGT1B | |
| SCHEMBL4893197 | 0.70 | FNTA (0.45) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | UNIVERSITY OF WASHINGTON (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | AKR1C3, NR1H3, HCCS | FNTA 18/4885FNTB 38/4885PGGT1B 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.